Drug intelligence / Profile preview

Alfaflor

Development stage
Unknown
Lead developer
Alfa Intes
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Alfaflor is an ophthalmic combination drug containing betamethasone (a corticosteroid), naphazoline (a vasoconstrictor), and tetracycline (a broad-spectrum antibiotic). Developed by Alfa Intes, it is approved in Italy as eye drops for the treatment of bacterial and non-bacterial (including allergic) conjunctivitis, dacryocystitis, dacryostenosis, blepharoconjunctivitis, eczematous dermatitis of the eyelids, and other ocular inflammations or infections susceptible to tetracycline. Betamethasone acts as an anti-inflammatory agent by activating the glucocorticoid receptor, naphazoline reduces ocular congestion and redness by stimulating alpha-adrenergic receptors to induce vasoconstriction, and tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

Brand names
Alfaflor
Other names
betamethasone + naphazoline + tetracyclinebetamethasone sodium phosphate + naphazoline nitrate + tetracycline hydrochloridetetracycline + betamethasone + naphazoline
02

Targets

Bacterial RibosomeADRA1A (α1A)ADRA2A (α2A)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Alfaflor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alfaflor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call